Merus N.V.
Develops multispecific antibody therapies that harness the immune system to fight cancer.
MRUS | NDAQ
Overview
Corporate Details
- ISIN(s):
- NL0011606264
- LEI:
- Country:
- United States of America
- Address:
- YALELAAN 62, 0 3584 CM UTRECHT
- Website:
- https://merus.nl/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Merus N.V. is a clinical-stage immuno-oncology company dedicated to the discovery and development of innovative therapeutics for cancer. The company specializes in creating full-length multispecific antibodies using its proprietary Multiclonics® platform, which includes bispecific (Biclonics®) and trispecific (Triclonics®) antibody formats. These therapeutics are designed to harness the patient's immune system to fight various types of cancer. Merus aims to develop potentially first-in-class and best-in-class treatments to address significant unmet medical needs for patients with cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Merus N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Merus N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Merus N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
